NCT03072797: BHAS

Beijing Hospital Atherosclerosis Study

Status unknown Last updated 27 April 2022

What this trial tests

trial in Atherosclerosis in 3,000 participants. Status unknown.

Timeline

16 March 2017

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Beijing Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	3,000
Start date	16 March 2017
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across China

Conditions studied

• Atherosclerosis — all drugs for Atherosclerosis →
• Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
• Coronary Artery Disease — all drugs for Coronary Artery Disease →
• Myocardial Ischemia — all drugs for Myocardial Ischemia →

Sponsor

Beijing Hospital

Who can join

18 and older, any sex, with Atherosclerosis or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Beijing Hospital Atherosclerosis Study (BHAS) is a prospective, single-center, observational cohort study performed at the Beijing Hospital in Beijing, China. Subjects enrolled in this study will be the consecutive patients undergoing coronary angiography in the hospital. Blood samples are taken immediately before the angiographic procedure. Clinical and angiographic characteristics are recorded. All patients will have routine follow-up at 6 months and 1 year postprocedure, then yearly thereafter. Follow-up includes mortality, myocardial infarction (MI), stroke, rehospitalization, coronary revascularization procedures, life styles, and medication use. The primary end point for the study will be the major adverse cardiovascular events (MACE), defined as death from any cause, nonfatal myocardial infarction, nonfatal stroke and revascularization. This study has been reviewed and approved by the Ethics Committee of Beijing Hospital. All enrolled individuals will be received written notice of the intended use of their blood samples and provided written consent.

The major objectives of the BHAS Study are to (1) establish a prospective cohort and a biological sample bank in ethnic Chinese with coronary angiography, (2) identify baseline new biosignature profiles such as novel biomarkers via metabolomics approach associated with the subsequent clinical events, (3) assess the use of molecular profiles from multiple platforms (eg, genomics, proteomics, and metabolomics) integrated with readily available clinical information for improved risk classification for cardiovascular events, and (4) provide clearer understanding of underlying disease processes.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

1. Nonlinear association of 1,5-anhydroglucitol with the prevalence and severity of coronary artery disease in chinese patients undergoing coronary angiography.
   Yang R, Zhang W, Wang X, Wang S, et al · · 2022 · cited 5× · PMID 36133308 · DOI 10.3389/fendo.2022.978520
2. Trimethylamine N-oxide predicts cardiovascular events in coronary artery disease patients with diabetes mellitus: a prospective cohort study.
   Yu X, Wang Y, Yang R, Wang Z, et al · · 2024 · cited 4× · PMID 39092284 · DOI 10.3389/fendo.2024.1360861
3. Prognostic Value of Serum 1,5-anhydroglucitol Levels in Patients with Acute Myocardial Infarction.
   Wang Y, Yang R, Zhang Y, Wang Z, et al · · 2022 · cited 1× · PMID 39076658 · DOI 10.31083/j.rcm2312394
4. Hematological parameters and major adverse cardiovascular events: a prospective study in a Chinese population involving 2,970 participants.
   Mu H, Wang X, Zhao X, Yang R, et al · · 2025 · PMID 40225871 · DOI 10.7150/ijms.104118
5. The relationship between serum 1,5-anhydroglucitol and adverse outcomes in acute coronary syndrome with and without chronic kidney disease patients.
   Wang Y, Wang Z, Yang R, Wang X, et al · · 2024 · PMID 39092257 · DOI 10.1016/j.heliyon.2024.e34179